Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy

CONCLUSIONS: Evidence from RCTs shows that IVIg improves disability for at least two to six weeks compared with placebo, with an NNTB of 4. During this period, IVIg probably has similar efficacy to oral prednisolone and IVMP. Further placebo-controlled trials are unlikely to change these conclusions. In one large trial, the benefit of IVIg compared with placebo in terms of improved disability score persisted for 24 weeks. Further research is needed to assess the long-term benefits and harms of IVIg relative to other treatments.PMID:38353301 | DOI:10.1002/14651858.CD001797.pub4
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Source Type: research